Comparisons of a multi-regional trial for four or five regions by fixed effect model and random effect model about allocating sample size rationally into individual regions for a multi-regional trial

References

• Chen, J, and H. Quan. 2016. Multiregional clinical trials for simultaneous global new drug development. Boca Rotan: CRC Press.
   Google Scholar
• Chow, S. C., J. Shao, and O. Y. P. Hu. 2002. Assessing sensitivity and similarity in bridging studies. Journal of Biopharmaceutical Statistics 12 (3):385–400. doi:10.1081/bip-120014567.
   PubMedGoogle Scholar
• Hsiao, C. F., Y. Y. Hsu, H. H. Tsou, and J. P. Liu. 2007. Use of prior information for Bayesian evaluation of bridging studies. Journal of Biopharmaceutical Statistics 17 (1):109–21. doi:10.1080/10543400601001501.
   PubMed Web of Science ®Google Scholar
• ICH, International Conference on Harmonisation. 1998. Tripartite guidance E5 ethnic factors in the acceptability of foreign data. The U.S. Federal Register 83:31790–6.
   Google Scholar
• Ikeda, I., and F. Bretz. 2010. Sample size and proportion of Japanese patients in multi-regional trials. Pharmaceutical Statistics 9 (3):207–16. doi:10.1002/pst.455.
   PubMed Web of Science ®Google Scholar
• Kawai, N., C. Stein, O. Komiyama, and Y. Li. 2008. An approach to rationalize partitioning sample size into individual regions in a multiregional trial. Drug Information Journal 42 (2):139–47. doi:10.1177/009286150804200206.
   Web of Science ®Google Scholar
• Ko, F. S., H. H. Tsou, J. P. Liu, and C. F. Hsiao. 2010. Sample size determination for a specific region in a multiregional trial. Journal of Biopharmaceutical Statistics 20 (4):870–85. doi:10.1080/10543401003618900.
   PubMed Web of Science ®Google Scholar
• Ko, F. S. 2012. Approaches to allocate sample size rationally into individual regions for a multi-regional trial under heterogeneous effect size. Communications in Statistics - Theory and Methods 41 (20):3648–65. doi:10.1080/03610926.2011.564741.
   Web of Science ®Google Scholar
• Ko, F. S. 2014. An approach to determine sample size and to allocate sample size for a specific region in a multiregional trial for survival (time-to-event) data under accelerated failure time model. Communications in Statistics – Theory and Methods 43 (23):4925–35. doi:10.1080/03610926.2012.717665.
   Web of Science ®Google Scholar
• Ko, F. S. 2015a. Sample size determination and rational partition for a multi-regional trial for survival (time-to-event) data with unrecognized heterogeneity that interacts with treatment. Communications in Statistics – Theory and Methods 44 (3):486–96. doi:10.1080/03610926.2012.750675.
   Web of Science ®Google Scholar
• Ko, F. S. 2015b. A statistical issue about a phase III multi-regional trial for the survival data under accelerated failure time model with unrecognized heterogeneity. Communications in Statistics – Theory and Methods 44 (12):2620–9. doi:10.1080/03610926.2013.786787.
   Web of Science ®Google Scholar
• Ko, F. S. 2016. Comparisons of allocating sample size rationally into individual regions under heterogeneous effect size in a multiregional trial by a fixed effect model and a random effect model. Communications in Statistics – Theory and Methods 45 (23):7060–74. doi:10.1080/03610926.2014.974823.
   Web of Science ®Google Scholar
• Ko, F. S. 2013. A design for survival studies: A multi-regional trial with unrecognized heterogeneity. Communications in Statistics – Theory and Methods 42 (13):2301–23. doi:10.1080/03610926.2011.599012.
   Web of Science ®Google Scholar
• Lan, G. K. K., Y. W. Soo, C. T. Siu, and M. Wang. 2005. The use of weighted Z-tests in medical research. Journal of Biopharmaceutical Statistics 15 (4):625–39. doi:10.1081/BIP-200062284.
   PubMed Web of Science ®Google Scholar
• Liu, J. P. S. C. Chow, and C. F. Hsiao. 2013. Design and analysis of bridging studies. Boca Rotan: CRC Press.
   Google Scholar
• Liu, J. P., C. F. Hsiao, and H. M. Hsueh. 2002. Bayesian approach to evaluation of bridging studies. Journal of Biopharmaceutical Statistics 12 (3):401–8. doi:10.1081/bip-120014568.
   PubMedGoogle Scholar
• Liu, J. P., H. M. Hsueh, and J. J. Chen. 2002. Sample size requirement for evaluation of bridging evidence. Biometrical Journal 44 (8):969–81. doi:10.1002/bimj.200290008.
   Web of Science ®Google Scholar
• Luo, X., W. J. Shih, S. P. Ouyang, and R. J. DeLap. 2010. An optimal adaptive design to address local regulations in global clinical trials. Pharmaceutical Statistics 9 (3):179–89. doi:10.1002/pst.456.
   PubMed Web of Science ®Google Scholar
• Quan, H., P. L. Zhao, J. Zhang, M. Roessner, and K. Aizawa. 2010a. Sample size considerations for Japanese patients in a multi-regional trial based on MHLW Guidance. Pharmaceutical Statistics 9 (2):100–12. doi:10.1002/pst.380.
   PubMed Web of Science ®Google Scholar
• Quan, H., M. Li, J. Chen, P. Gallo, B. Binkowitz, E. Ibia, Y. Tanaka, S. P. Ouyang, X. Luo, G. Li, et al. 2010b. Assessment of consistency of treatment effects in multiregional clinical trials. Drug Information Journal 44 (5):617–32. doi:10.1177/009286151004400509.
   Web of Science ®Google Scholar
• Shih, W. J. 2001. Clinical trials for drug registration in Asian-Pacific countries: Proposal for a new paradigm from a statistical perspective. Controlled Clinical Trials 22 (4):357–66. doi:10.1016/S0197-2456(01)00138-6.
   PubMedGoogle Scholar
• Tsou, H. H., T. Y. Chien, J. P. Liu, and C. F. Hsiao. 2011. A consistency approach to evaluation of bridging studies and multi-regional trials. Statistics in Medicine 30 (17):2171–86. doi:10.1002/sim.4251.
   PubMed Web of Science ®Google Scholar